In 2015, facing regulatory threats to their consumer tech business, the company pivoted to enterprise, a risky move that paid off, highlighting the importance of adapting to market shifts. With the Trump administration looming in 2025, businesses must prepare for potential policy changes impacting sourcing and compliance. Lessons learned include the need for diverse revenue streams, leveraging AI for business outcomes, and building resilient supply chains to navigate uncertain times and thrive in the evolving landscape.
Full Article
Wave (WVE) Q2 Revenue Drops 56%
Wave Life Sciences (NASDAQ:WVE) reported disappointing Q2 2025 earnings, with revenue of $8.7 million falling short of the $13.2 million forecast and a loss per share of $0.31 versus the anticipated $0.28. Despite a 55.8% year-over-year revenue decline and increased operating expenses, the company made progress in its RNA-based medicine pipeline using its proprietary PRISM platform. Want More Context? 🔎
Read more